AU2016226103A1 - Uses of PTHrP analogue in reducing fracture risk - Google Patents

Uses of PTHrP analogue in reducing fracture risk Download PDF

Info

Publication number
AU2016226103A1
AU2016226103A1 AU2016226103A AU2016226103A AU2016226103A1 AU 2016226103 A1 AU2016226103 A1 AU 2016226103A1 AU 2016226103 A AU2016226103 A AU 2016226103A AU 2016226103 A AU2016226103 A AU 2016226103A AU 2016226103 A1 AU2016226103 A1 AU 2016226103A1
Authority
AU
Australia
Prior art keywords
abaloparatide
bmd
bone
teriparatide
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016226103A
Other languages
English (en)
Inventor
Gary Hattersley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Radius Health Inc
Original Assignee
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56849024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2016226103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Radius Health Inc filed Critical Radius Health Inc
Publication of AU2016226103A1 publication Critical patent/AU2016226103A1/en
Priority to AU2020267182A priority Critical patent/AU2020267182A1/en
Priority to AU2024202952A priority patent/AU2024202952A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2016226103A 2015-03-03 2016-03-03 Uses of PTHrP analogue in reducing fracture risk Abandoned AU2016226103A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020267182A AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk
AU2024202952A AU2024202952A1 (en) 2015-03-03 2024-05-03 Uses of PTHrP analogue in reducing fracture risk

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562127729P 2015-03-03 2015-03-03
US62/127,729 2015-03-03
US201562165841P 2015-05-22 2015-05-22
US62/165,841 2015-05-22
US201562201564P 2015-08-05 2015-08-05
US62/201,564 2015-08-05
US201562239733P 2015-10-09 2015-10-09
US62/239,733 2015-10-09
US201662278762P 2016-01-14 2016-01-14
US62/278,762 2016-01-14
PCT/US2016/020787 WO2016141250A1 (en) 2015-03-03 2016-03-03 USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267182A Division AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk

Publications (1)

Publication Number Publication Date
AU2016226103A1 true AU2016226103A1 (en) 2017-08-31

Family

ID=56849024

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016226103A Abandoned AU2016226103A1 (en) 2015-03-03 2016-03-03 Uses of PTHrP analogue in reducing fracture risk
AU2020267182A Abandoned AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk
AU2024202952A Pending AU2024202952A1 (en) 2015-03-03 2024-05-03 Uses of PTHrP analogue in reducing fracture risk

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020267182A Abandoned AU2020267182A1 (en) 2015-03-03 2020-11-10 Uses of PTHrP analogue in reducing fracture risk
AU2024202952A Pending AU2024202952A1 (en) 2015-03-03 2024-05-03 Uses of PTHrP analogue in reducing fracture risk

Country Status (8)

Country Link
US (10) US20170065682A1 (cg-RX-API-DMAC10.html)
EP (2) EP4137147A3 (cg-RX-API-DMAC10.html)
JP (5) JP6755256B2 (cg-RX-API-DMAC10.html)
AU (3) AU2016226103A1 (cg-RX-API-DMAC10.html)
CA (1) CA2977812A1 (cg-RX-API-DMAC10.html)
DK (1) DK3265115T3 (cg-RX-API-DMAC10.html)
ES (1) ES2927067T3 (cg-RX-API-DMAC10.html)
WO (1) WO2016141250A1 (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2904891T3 (es) 2016-04-18 2022-04-06 Radius Health Inc Formulaciones de abaloparatida, parche transdérmico de la misma y usos de la misma
IL266977B2 (en) * 2016-11-30 2024-01-01 Purdue Research Foundation Fracture-targeted bone regeneration using thyroid hormone receptor stimulation
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
IL284533B2 (en) * 2019-01-11 2024-02-01 Radius Health Inc Methods for detecting antibodies to neutralizing thyroid hormone (PTH) and thyroid hormone-related peptide (PTHRP) analog
WO2020166561A1 (ja) 2019-02-14 2020-08-20 富士フイルム株式会社 骨折リスク評価値取得装置及びその作動方法並びに骨折リスク評価値取得プログラム
BR112022004462A2 (pt) * 2019-09-12 2022-05-31 Radius Health Inc Métodos para melhorar a fusão espinhal com abaloparatida
CN112646042A (zh) 2019-10-10 2021-04-13 陕西麦科奥特科技有限公司 活性多肽化合物
MX2023004796A (es) * 2020-10-26 2023-07-18 Purdue Research Foundation Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
JP2024502334A (ja) * 2021-01-05 2024-01-18 ラジウス ヘルス，インコーポレイテッド アバロパラチドを用いた長骨骨折の治療
EP4346878A1 (en) * 2021-05-25 2024-04-10 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU2003207512B2 (en) * 2002-01-10 2008-06-12 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
CA2621264A1 (en) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Parathyroid hormone analogues and methods of use
US8207115B2 (en) * 2006-08-25 2012-06-26 Ares Trading S.A. Treatment of cartilage disorders with FGF-18
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
DK2073789T3 (da) * 2006-10-03 2019-08-05 Radius Health Inc Stabil sammensætning omfattende et knogle-anabolisk protein, nemlig en pthrp-analog, og anvendelser deraf
WO2010022176A1 (en) * 2008-08-19 2010-02-25 Ferring International Center S.A. Methods of treatment for skeletal conditons
KR20140047043A (ko) * 2011-04-22 2014-04-21 라디우스 헬쓰, 인코포레이티드 PTH, PTHrP를 위한 약물 전달 방법 및 관련 펩티드
US9421245B2 (en) * 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
HRP20211127T1 (hr) * 2015-10-09 2021-10-15 Radius Health, Inc. Formulacije analoga pthrp, njihovi transdermalni flasteri, i njihova uporaba

Also Published As

Publication number Publication date
EP3265115A4 (en) 2019-05-22
US20260144851A1 (en) 2026-05-28
DK3265115T3 (da) 2022-09-05
EP4137147A3 (en) 2023-04-05
JP2020189884A (ja) 2020-11-26
JP2022075999A (ja) 2022-05-18
US20220125887A1 (en) 2022-04-28
US20170368148A1 (en) 2017-12-28
EP4137147A2 (en) 2023-02-22
US20230381283A1 (en) 2023-11-30
US20200376088A1 (en) 2020-12-03
US20250387454A1 (en) 2025-12-25
US20250195619A1 (en) 2025-06-19
ES2927067T3 (es) 2022-11-02
US20170065682A1 (en) 2017-03-09
US20230321199A1 (en) 2023-10-12
WO2016141250A1 (en) 2016-09-09
JP2023129523A (ja) 2023-09-14
JP2025100689A (ja) 2025-07-03
EP3265115A1 (en) 2018-01-10
JP6755256B2 (ja) 2020-09-16
JP2018508530A (ja) 2018-03-29
AU2020267182A1 (en) 2020-12-03
AU2024202952A1 (en) 2024-05-23
JP7049412B2 (ja) 2022-04-06
EP3265115B1 (en) 2022-06-22
CA2977812A1 (en) 2016-09-09
US20200061160A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US20250195619A1 (en) Uses of pthrp analogue in reducing fracture risk
Tay et al. Discontinuing denosumab: can it be done safely? A review of the literature
CZ20004134A3 (cs) Léčivo pro snížení rizika vertebrální nebo nevertebrální zlomeniny kosti u člověka a rizika osteoporózy
Chew et al. Abaloparatide: recombinant human PTHrP (1–34) anabolic therapy for osteoporosis
CZ2000862A3 (cs) Léčivo pro hojení kostí a reparaci zlomenin
Kim et al. Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition
US20050192227A1 (en) Method for reducing the risk of cancer
HK40088026A (en) Uses of abaloparatide in reducing fracture risk
US20220378881A1 (en) Treatment and prevention of osteoporosis in high body mass index individuals
Cosman Teriparatide and abaloparatide treatment for osteoporosis
Tabacco et al. PTH and PTHrP analogs: Treatment of osteoporosis
Lim et al. Therapeutic Approaches to
ADAMI et al. Parathyroid hormone and
Mass et al. Current Issues in Osteoporosis Therapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted